Skip to main content
Retour
ARQT logo

Arcutis Biotherapeutics, Inc.

Qualité des données : 100%
ARQT
NASDAQ Healthcare Biotechnology
21,83 €
▼ 0,46 € (-2,06%)
Cap. Boursière : 2,71B
Fourchette du Jour
21,58 € 22,25 €
Fourchette 52 Semaines
11,86 € 31,77 €
Volume
753 317
Moyenne 50J / 200J
25,67 € / 21,49 €
Clôture Précédente
22,29 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -167,8 0,3
P/B 14,3 2,9
ROE % -9,3 3,7
Net Margin % -4,3 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
33,33 € +52.7%
Low: 29,00 € High: 37,00 €
P/E Prévisionnel
65,9
BPA Prévisionnel
0,34 €
Croissance BPA (est.)
+0,0%
CA Est.
500 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 3,06 €
2,99 € – 3,22 €
1,1 B 2
FY2029 2,63 €
2,57 € – 2,77 €
920 M 4
FY2028 1,99 €
1,44 € – 2,79 €
780 M 6

Points Clés

Debt/Equity of 0,03 — conservative balance sheet
Negative free cash flow of -6,31M
Capital efficient — spends only 0,18% of revenue on capex

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)91,34%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-9,30%
ROIC-4,68%
Net Margin-4,29%
Op. Margin-3,25%

Sécurité

Debt / Equity
0,03
Current Ratio3,17
Interest Coverage-1,01

Valorisation

P/E Ratio
-167,75
P/B Ratio14,29
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 91,34% Revenue Growth (3Y) 151,18%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 376,07M Net Income (TTM) -16,14M
ROE -9,30% ROA -3,73%
Gross Margin 90,24% Operating Margin -3,25%
Net Margin -4,29% Free Cash Flow (TTM) -6,31M
ROIC -4,68% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,03 Current Ratio 3,17
Interest Coverage -1,01 Dividend Yield 0,00%
Valuation
P/E Ratio -167,75 P/B Ratio 14,29
P/S Ratio 7,20 PEG Ratio 2,58
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 2,71B Enterprise Value 2,67B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 376,07M 196,54M 59,61M 3,69M 0,0
Net Income -16,14M -140,04M -262,14M -311,46M -206,36M
EPS (Diluted) -0,13 -1,16 -3,78 -5,66 -4,17
Gross Profit 339,38M 177,41M 54,62M 2,93M -763 000,0
Operating Income -12,23M -128,40M -241,10M -301,63M -206,53M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 432,97M 348,89M 341,37M 449,27M 408,15M
Total Liabilities 243,49M 191,35M 252,70M 239,69M 110,48M
Shareholders' Equity 189,48M 157,54M 88,67M 209,58M 297,68M
Total Debt 6,27M 110,59M 205,92M 202,54M 77,56M
Cash & Equivalents 42,91M 71,34M 88,40M 53,64M 97,99M
Current Assets 411,23M 335,82M 330,43M 437,41M 402,77M
Current Liabilities 129,84M 81,01M 46,67M 37,81M 33,33M